Pacific BiosciencesPACB
PACB
About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Employees: 796
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
64% more call options, than puts
Call options by funds: $6.83M | Put options by funds: $4.17M
20% more capital invested
Capital invested by funds: $395M [Q3] → $475M (+$80.5M) [Q4]
15% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 65
9.67% more ownership
Funds ownership: 85.1% [Q3] → 94.77% (+9.67%) [Q4]
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
0% less funds holding
Funds holding: 226 [Q3] → 225 (-1) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.50
36%
upside
Avg. target
$2.20
100%
upside
High target
$3
173%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
Canaccord Genuity Kyle Mikson 34% 1-year accuracy 10 / 29 met price target | 173%upside $3 | Buy Maintained | 10 Apr 2025 |
Scotiabank Sung Ji Nam 8% 1-year accuracy 2 / 24 met price target | 82%upside $2 | Sector Outperform Maintained | 25 Mar 2025 |
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target | 82%upside $2 | Neutral Reiterated | 20 Feb 2025 |
Goldman Sachs Matthew Sykes 43% 1-year accuracy 15 / 35 met price target | 36%upside $1.50 | Neutral Maintained | 18 Feb 2025 |
Stephens & Co. Mason Carrico 15% 1-year accuracy 4 / 26 met price target | 127%upside $2.50 | Overweight Reiterated | 18 Feb 2025 |
Financial journalist opinion
Based on 5 articles about PACB published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry
Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs
Positive
Zacks Investment Research
5 days ago
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.17, marking no change from the previous day.
Neutral
GlobeNewsWire
1 week ago
Davos Alzheimer's Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer's Disease Research in North Africa
International research team aims to develop better understanding of Alzheimer's disease and dementia in diverse populations International research team aims to develop better understanding of Alzheimer's disease and dementia in diverse populations
Neutral
GlobeNewsWire
2 weeks ago
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million
Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025.
Neutral
GlobeNewsWire
3 weeks ago
PacBio Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 342,432 shares of PacBio common stock to the Company's recently hired Chief Financial Officer, Jim Gibson, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on March 31, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
Neutral
Market Watch
1 month ago
Pacific Biosciences Names Jim Gibson Chief Financial Officer
Pacific Biosciences of California has hired Jim Gibson as its new chief financial officer, effective March 31.
Neutral
GlobeNewsWire
1 month ago
Jim Gibson to join PacBio as Chief Financial Officer
MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations.
Neutral
Zacks Investment Research
1 month ago
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
Pacific Biosciences of California (PACB) reachead $1.26 at the closing of the latest trading day, reflecting a +0.8% change compared to its last close.
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Retain PacBio Stock in Your Portfolio Now
PACB continues to deliver growth from its unique technologies amid macroeconomic concerns.
Neutral
GlobeNewsWire
1 month ago
Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes
MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for high-precision variant detection and copy number analysis in 316 previously inaccessible segmental duplication regions, including 9 challenging medically-relevant genes.
Charts implemented using Lightweight Charts™